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There is marked heterogeneity amongst people aged over 65 years. Some of this may be captured by increasing chronological age. However, much of this variability is thought to be due to biological age or frailty \[[@CR1]\]. Frailty is a state of vulnerability that carries an increased risk of poor outcomes in older adults \[[@CR1]\]. The prevalence and clinical importance of frailty are increasing with ageing of the population \[[@CR1], [@CR2]\]. Frailty is associated with changes in inflammation, coagulation, and possibly platelet function \[[@CR3], [@CR4]\].

Atrial fibrillation (AF) is a common cardiac arrhythmia in older adults. The prevalence of AF in published studies in Western countries ranges from 0.5% to 3% in the general population, 5--6% in people older than 65 years, and up to 5--15% among those aged 80 years or older \[[@CR5]--[@CR7]\]. Treatment of AF aims at stroke prevention with antithrombotic therapy, reducing symptoms with rate-control or rhythm-control strategies, and management of associated medical conditions \[[@CR8]\]. According to the current guidelines, aspirin is not recommended for stroke prevention in AF unless patients refuse the use of any oral anticoagulant \[[@CR9], [@CR10]\]. International drug utilization studies show that, in practice, 17--45% of older adults use aspirin for stroke prevention in AF \[[@CR11]--[@CR14]\]. The evidence for stroke prevention in AF with aspirin is weak and the risk of major bleeding with aspirin is not significantly different to that of oral anticoagulants, especially in older people \[[@CR9], [@CR15], [@CR16]\].

The efficacy of antiplatelet drugs has not been rigorously tested in older people and older people are generally more vulnerable to adverse drug effects due to changes in pharmacokinetics and pharmacodynamics associated with aging and an increased risk of drug--drug and drug--disease interactions in the presence of polypharmacy and multimorbidity \[[@CR17]\]. In frail older people, it is unclear whether response to antiplatelet therapies is altered. Some studies have suggested that platelet aggregability may increase in old age \[[@CR4], [@CR18], [@CR19]\] and plasma aspirin esterase activity is reduced in frail people \[[@CR20]--[@CR22]\]. However, there has been no study exploring the association between frailty and platelet aggregation. Therefore, the aims of this study were to investigate the effects of frailty and chronological age on platelet aggregability and on platelet responses to aspirin in older patients with AF.

Methods {#Sec2}
=======

A total of 302 inpatients aged ≥65 years with AF at Royal North Shore Hospital, a tertiary referral teaching hospital in Sydney, Australia, were recruited for a study of anticoagulant utilization and outcomes in frail and non-frail older inpatients with AF. Of these patients, 134 participated in this sub-study on platelet aggregation. Among these patients, 82 who were not taking any antiplatelet drugs for at least a week before blood samples were taken for testing and 33 patients who were taking regular aspirin (100 mg daily) and no other antiplatelet agents were eligible for this analysis. Informed consent was obtained from all participants or their caregivers. The study was approved by The Northern Sydney Local Health District Human Research Ethics Committee and The University of Sydney Human Research Ethics Committee. All procedures followed were in accordance with the ethical standards of the responsible committee on human experimentation (institutional and national) and with the Helsinki Declaration of 1964, as revised in 2013.

Frailty was determined using the Reported Edmonton Frail Scale \[[@CR23]\]. This scale, which was adapted from the Edmonton Frail Scale for use in Australian acute inpatients, assesses nine frailty domains: cognition, general health status, functional independence, social support, medication use, nutrition, mood, continence, and reported functional performance. With a maximum score of 18, a score of 0--5 indicates robust, 6--7 indicates apparently vulnerable status, 8--9 mild frailty, 10--11 moderate frailty, and 12 or higher indicates severe frailty. The cut-off point to identify frailty is 8 \[[@CR23]\].

Blood was collected from the participants in the morning from the antecubital vein into tubes containing hirudin. Platelet aggregation studies were performed between 30 min and 2 h after blood was taken, using whole blood impedance aggregometry (WBIA, Multiplate Analyser, Roche Diagnostics). The Multiplate Analyser measures aggregation in whole blood samples through changes in electrical impedance between two electrodes and has been applied to detect platelet inhibition by aspirin in many studies \[[@CR24]--[@CR29]\]. More details about the test have been described elsewhere \[[@CR30], [@CR31]\]. Platelet agonists used in this assay were arachidonic acid (ASPItest) to trigger arachidonic acid-induced platelet aggregation, which is affected by aspirin; adenosine diphosphate (ADPtest) to trigger ADP-induced platelet aggregation, which is affected by thienopyridines (e.g., clopidogrel, prasugrel, ticlopidine); and Thrombin Receptor Activating Peptide 6 (TRAPtest) to trigger TRAP-6 induced platelet aggregation, which is only affected by glycoprotein IIb/IIIa receptor antagonists (e.g., tirofiban, abciximab, eptifibatide). ADPtest and TRAPtest were used as positive controls for platelet reactivity. Platelet aggregation is defined by the area under the aggregation-time curve, which represents the aggregation over 6 min, and values are reported in arbitrary aggregation units (AU). Suggested normal ranges in healthy blood donors as provided by the manufacturer are 71--115 AU for the ASPItest, 57--113 AU for the ADPtest, and 84--128 AU for the TRAPtest \[[@CR32]\].

Analysis of the data was performed using SPSS for Windows 20.0 (IBM Corp., Armonk, NY, USA). Continuous variables are presented as mean ± standard deviation, and categorical variables as frequency and percentage. Clinical characteristics and laboratory parameters were compared between frailty and treatment groups using the Mann--Whitney *U* test for continuous variables, and Chi-square or Fisher's exact test for binary variables. Correlation of platelet aggregation with age, frailty score, and other variables that have previously been shown to have an impact on platelet aggregation \[[@CR33]\] was assessed with Spearman correlation. Two-sided *p* values \<0.05 were considered significant. Platelet function was considered separately for each treatment regimen and by frailty status. The platelet counts in this study showed a marked degree of variation (mean 220 ± 95 × 10^9^/l, median 202 × 10^9^/l, range 30--502 × 10^9^/l). Twenty-five patients had platelet counts below the normal range, and, as expected, these patients had significantly lower AU values than patients with platelet counts in the normal range (*p* \< 0.001). Spearman correlation also showed that platelet count had a very strong association with platelet aggregation (*r* = 0.59, *p* \< 0.001 for ASPI test; *r* = 0.63, *p* \< 0.001 for ADP test; *r* = 0.69, *p* \< 0.001 for TRAP test). Therefore, we adjusted the test results to control for the effect of the platelet counts and provide a purer representation of platelet aggregability by dividing the AU value by the platelet count, giving a value of AU per platelet. We compared aggregability between frail and non-frail participants with and without aspirin treatment based on these adjusted values. Sensitivity analyses were also performed to assess the robustness of the finding after excluding those participants with platelet counts \<100 × 10^9^/l or \>400 × 10^9^/l.

Results {#Sec3}
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A total of 115 participants were included in the study (mean age 85 ± 6 years, age range 71--97 years, 41% female, 52% frail). Among the 82 participants who did not take any antiplatelet therapy in the week prior to sampling (Table [1](#Tab1){ref-type="table"}), mean age was 84 ± 6 years and 49% of the participants were frail. Compared to the non-frail, frail participants had a significantly higher score on the Charlson Comorbidity Index, with a higher prevalence of heart failure and renal impairment. There was no quantitative difference in any of the platelet-aggregation assays between frail and non-frail participants. Spearman correlation coefficients were performed for each test of platelet aggregation with age, frailty score, and other variables that may impact platelet aggregation (Table [2](#Tab2){ref-type="table"}). There were no significant correlations between platelet aggregation and any of these variables.Table 1Characteristics of 82 participants not taking any antiplatelet therapyAll (*n* = 82)Frail (*n* = 40)Non-frail (*n* = 42)*p* valuesAge (years)84.00 ± 6.0884.98 ± 6.4083.05 ± 5.670.08Female gender33 (40.20%)18 (45.00%)15 (35.70%)0.39Hypertension51 (62.20%)23 (57.50%)28 (66.70%)0.39Heart failure38 (46.30%)24 (60.00%)14 (33.30%)0.02Ischemic heart disease35 (42.70%)18 (45.00%)17 (40.50%)0.68Diabetes mellitus type 215 (18.30%)9 (22.50%)6 (14.30%)0.31Dyslipidemia25 (30.50%)10 (25.00%)15 (35.70%)0.29Peripheral vascular disease8 (9.80%)7 (17.50%)1 (2.40%)0.02Stroke24 (29.30%)13 (32.50%)11 (26.20%)0.53History of cancer/current cancer22 (26.80%)10 (25.00%)12 (28.60%)0.72Female gender37 (45.10%)25 (62.50%)12 (28.60%)0.002Reported Edmonton Frail Score7.48 ± 2.849.88 ± 1.645.19 ± 1.55\<0.001Charlson Comorbidity Index3.84 ± 2.304.50 ± 2.103.21 ± 2.320.004Hemoglobin (g/l)178 ± 122119 ± 21125 ± 210.26White cell count (×10^9^/l)7.43 ± 2.537.34 ± 2.407.50 ± 2.680.99Platelet count (×10^9^/l)226 ± 92217 ± 107234 ± 740.22Platelet aggregation (AU) ADPtest58 ± 2656 ± 2860 ± 240.29 ASPItest68 ± 2865 ± 3070 ± 260.41 TRAPtest77 ± 2975 ± 3280 ± 260.53Adjusted platelet aggregation (AU per platelet) ASPItest0.31 ± 0.090.31 ± 0.110.30 ± 0.070.43 ADPtest0.26 ± 0.110.27 ± 0.120.26 ± 0.100.95 TRAPtest0.36 ± 0.130.37 ± 0.150.35 ± 0.110.81Continuous data are presented as mean ± standard deviation or median (range). Categorical data are shown as *n* (%)Table 2Spearman correlation coefficients for platelet aggregation with age, frailty scores, and other variables in 82 participants not taking antiplatelet agentsVariablesASPI test (AU per platelet)ADP test (AU per platelet)TRAP test (AU per platelet)Age (years)0.100.100.05Reported Edmonton Frail Score−0.030.120.01Charlson Comorbidity Index−0.150.010.02Body mass index (kg/m^2^)0.010.090.11Dyslipidemia−0.18−0.07−0.12Diabetes mellitus0.100.190.14Heart failure−0.010.130.06Ischemic heart disease−0.06−0.13−0.05History of cancer/current cancer−0.040.030.09Female gender0.040.010.09Anticoagulant users (warfarin/heparin)−0.07−0.07−0.01Hemoglobin (g/dl)−0.17−0.16−0.09White cell count (×10^9^/l)0.090.16−0.08A positive correlation indicates that the variable is associated with increased platelet aggregation. All *p* values were \>0.05

Among the 33 participants who were taking aspirin, the frail (*n* = 20) had higher ASPI test results than the non-frail (0.11 ± 0.11 AU per platelet in the frail versus 0.05 ± 0.04 AU per platelet in the non-frail; *p* = 0.04), suggesting that platelets in the frail are less responsive to aspirin (Table [3](#Tab3){ref-type="table"}). Representative curves from the ASPI tests of a frail and non-frail participant are shown in Fig. [1](#Fig1){ref-type="fig"}. Spearman correlation coefficients of the ASPI test results with age, frailty score and other variables found that the only significant correlation was of the presence of a diagnosis of heart failure with increased AU (correlation coefficient 0.40, *p* = 0.02) (Table [4](#Tab4){ref-type="table"}). Sensitivity analyses showed that the difference between the frail and the non-frail remained significant amongst the participants with platelet counts from 100--400 × 10^9^/l (*n* = 26), consistent with the analyses amongst those with platelet counts from 30--502 × 10^9^/l (*n* = 33) (Table [5](#Tab5){ref-type="table"}).Table 3Characteristics of the 33 participants taking aspirinAll (*n* = 33)Frail (*n* = 20)Non-frail (*n* = 13)*p* valuesAge (years)86.52 ± 6.9086.60 ± 6.6486.38 ± 7.570.96Reported Edmonton Frail Score8.03 ± 2.699.75 ± 1.485.38 ± 1.81\<0.001Charlson3.33 ± 2.033.55 ± 2.043.00 ± 2.040.52Female gender14 (42.40%)6 (30.00%)8 (61.50%)0.07Hypertension22 (66.70%)14 (70.00%)8 (61.50%)0.61Heart failure15 (45.50%)13 (65.00%)2 (15.40%)0.005Ischemic heart disease16 (48.50%)11 (55.00%)5 (38.50%)0.35Diabetes mellitus type 26 (18.20%)4 (20.00%)2 (15.40%)1.00Dyslipidemia9 (27.30%)7 (35.00%)2 (15.40%)0.26Peripheral vascular disease5 (15.20%)4 (20.00%)1 (7.70%)0.63Stroke9 (27.30%)5 (25.00%)4 (30.80%)0.72Cancer7 (21.20%)5 (25.00%)2 (15.40%)0.67eGFR \<60(ml/min/1.73 m^2^)15 (45.50%)7 (35.00%)8 (61.50%)0.14Hemoglobin (g/l)114 ± 19112 ± 21116 ± 160.41White cell count (×10^9^/l)7.69 ± 2.898.11 ± 3.377.08 ± 1.930.34Platelet count (×10^9^/l)205 ± 104186 ± 100235 ± 1070.28Platelet aggregation (AU) ASPItest15 ± 1318 ± 1511 ± 80.21 ADPtest51 ± 3147 ± 3158 ± 310.37 TRAPtest66 ± 3461 ± 3574 ± 310.27Adjusted platelet aggregation (AU per platelet) ASPItest0.09 ± 0.090.11 ± 0.110.05 ± 0.040.04 ADPtest0.25 ± 0.090.25 ± 0.100.24 ± 0.071.00 TRAPtest0.35 ± 0.170.36 ± 0.210.33 ± 0.090.90Continuous data are presented as mean ± SD. Categorical data are shown as *n* (%)*eGFR* estimated glomerular filtration rateFig. 1Arachidonic acid-induced platelet aggregation (ASPItest) in participants taking aspirin. **a** From a representative frail participant. **b** From a representative non-frail participant. (One Multiplate test cell includes two independent sensor units. The increase of impedance due to the attachment of platelets to the electrodes is detected for each sensor unit separately and transformed to arbitrary aggregation units that are plotted against time. The duplicate sensors work as an internal control) \[[@CR24]\]Table 4Spearman correlation for platelet aggregation in response to aspirin with age, frailty score, and other variables in 33 participants taking aspirinVariablesASPI test (AU per platelet)*p* valuesAge (years)0.030.87Reported Edmonton Frail Score0.190.29Charlson Comorbidity Index0.100.56Body mass index (kg/m^2^)0.300.24Dyslipidemia0.160.38Diabetes mellitus0.140.44Heart failure0.400.02Ischemic heart disease0.190.29History of cancer/current cancer−0.170.34Female gender−0.080.64Anticoagulant users (warfarin/heparin)0.200.26Hemoglobin (g/dl)0.040.84White cell count (×10^9^/l)0.290.11A positive correlation indicates that the variable is associated with increased arachidonic acid-induced platelet aggregation (e.g., less responded to aspirin)Table 5Results from sensitivity analyses assessing the impact of frailty on antiplatelet responsivenessAllFrailNon-frail*p* valuesAll participants on aspirin (platelet counts 30--502 × 10^9^/l)*N* = 33*N* = 20*N* = 13Adjusted platelet aggregation (AU per platelet) ASPItest0.090 ± 0.0900.110 ± 0.1100.050 ± 0.0350.036 ADPtest0.245 ± 0.0910.252 ± 0.1040.241 ± 0.0681.000 TRAPtest0.349 ± 0.1730.363 ± 0.2130.327 ± 0.0880.899Participants with platelet counts\
100--400 × 10^9^/l*N* = 26*N* = 15*N* = 11Adjusted platelet aggregation (AU per platelet) ASPItest0.078 ± 0.0560.096 ± 0.0630.055 ± 0.0360.047 ADPtest0.241 ± 0.0920.240 ± 0.1050.243 ± 0.0750.799 TRAPtest0.329 ± 0.1330.322 ± 0.1600.339 ± 0.0890.540

Discussion {#Sec4}
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In this pilot study of older inpatients with AF, there was no significant relationship between platelet aggregation and chronological age. This result is different to many previous studies in which there was a trend towards increased platelet aggregation with age \[[@CR4], [@CR18], [@CR19], [@CR33]\]. However, all of these studies were designed to compare platelet aggregation between younger groups and older groups (participant age ranged from around 20 to 80 years old, with the cut-off point to determine older groups usually around 60 years old). In contrast, in our study the mean age of participants was around 84--86 years, with an age range from 71 to 97 years. Furthermore, unlike our study of acutely unwell older inpatients, previous studies demonstrating increased platelet aggregation with age were in healthy volunteers from the community without a history of cardiovascular disease. Additionally, in this study we used the Multiplate assay---a new method to evaluate platelet aggregation, which is different from light transmission aggregometry that was used in previous studies \[[@CR4], [@CR18], [@CR19], [@CR33]\].

Amongst participants not taking antiplatelet drugs, there was no association between frailty status, a marker of biological age, and platelet aggregation. Amongst those taking aspirin, there was a significant difference in platelet aggregation to arachidonic acid (ASPI test): the frail exhibited a degree of aspirin resistance compared to the non-frail. The reduced responsiveness to aspirin observed in the frail may be partly attributed to the higher prevalence of heart failure in the frail participants. In participants taking aspirin, we found a moderate positive correlation between heart failure and arachidonic acid-induced platelet aggregation, which means that compared to participants without a history of heart failure, those with heart failure tend to have a higher on-treatment platelet aggregation. The relationship between heart failure and decreased aspirin effectiveness has been reported in several studies \[[@CR34], [@CR35]\]. Although not comprehensively understood, this could be explained by several mechanisms such as increased levels of circulating catecholamines, angiotensin II and b-thromboglobulin, platelet factor 4, P-selectin, and platelet-endothelial cell adhesion molecules in patients with heart failure \[[@CR36]\]. The observed reduced platelet responsiveness to aspirin in the frail supports the current guidelines that do not recommend aspirin for stroke prevention in AF, and raises a question about the risk-to-benefit ratio of aspirin prescription in older patients with AF, which ironically is more common in the frail \[[@CR37]\], in whom prescribers may be more concerned about using anticoagulants.

The study comprised a sample of very old and frail people, who are often excluded from studies \[[@CR38]\]. Recently, objective measures of frailty, including the Reported Edmonton Frail Scale used in our study \[[@CR23]\], have facilitated study of the physiology and management of frailty \[[@CR1]\]. The physiological etiology of frailty is still not comprehensively understood. Multiple physiological factors are thought to be involved in the development of frailty, including activation of inflammation, coagulation systems, and changes in pharmacokinetics and pharmacodynamics \[[@CR1], [@CR3], [@CR21], [@CR39]\]. Studies measuring individual factors in the coagulation system suggest that frailty is associated with pro-coagulant changes such as increased plasma fibrinogen, factor VIII, C-reactive protein, D-dimer, and tissue plasminogen activator (t-PA) plasma levels \[[@CR40]--[@CR43]\]. To our knowledge, there has been no previous study focusing on the impact of frailty on platelet aggregation and platelet response to antiplatelet drugs. There have only been several studies reporting the association between frailty and reduced activity of plasma aspirin esterase, a hydrolysis enzyme that helps the conversion of aspirin (acetylsalicylic acid) to salicylic and acetic acid \[[@CR20], [@CR21]\].

In this study, we used the Multiplate method to study platelet aggregation. Since the introduction of the bleeding time test, different methodologies have been developed to obtain the optimal platelet function test and to assess platelet reactivity in response to antiplatelet drugs \[[@CR44]--[@CR47]\]. The Multiplate is a new method for evaluating platelet aggregation and is one of the point-of-care assays for monitoring antiplatelet therapy \[[@CR30]\]. It can be performed in whole blood, does not require specifically trained laboratory personnel, and is simple to interpret \[[@CR45]\]. This method has been widely used in clinical trials and is also implemented in daily practice in catheterization laboratories, predominantly in Europe \[[@CR44]\]. However, it should be noted that the correlation of this test with other tests of platelet aggregation and with clinical outcomes is not perfect \[[@CR29], [@CR48]\] and that this test has not been validated in very old or frail participants. The Multiplate assay provides a reproducible measure of reduced platelet aggregation in response to defined agonists. However, unlike assays measuring platelet response to very low doses of agonists, which were used in previous studies of platelet function in ageing \[[@CR4], [@CR18], [@CR19], [@CR33]\], the Multiplate assay is not designed to detect platelet hyperaggregability.

A major limitation of this study is that it was done in the acute care setting, in which platelet aggregation may be influenced by acute inflammation \[[@CR49]\]. This is a pilot study testing the hypothesis of altered platelet aggregation with frailty that relies on a convenience sample. Small sample size may have limited the power of this study to observe small changes with age and frailty. This study sample is based on volunteers from inpatients recruited for a study on anticoagulant utilization. Approximately half of the participants in that study agreed to a blood test, so the sample may be not representative of older inpatients with AF. Furthermore, all of the participants in this study had AF, which may be procoagulant \[[@CR50]\]. Therefore, results should be cautiously interpreted and generalized to older inpatients without AF who may be prescribed aspirin for other indications.

Conclusions {#Sec5}
===========

We found no effect of chronological age or frailty status on platelet aggregation amongst hospitalized older patients with AF in this pilot study. Response to aspirin is reduced in the frail and in those with heart failure. This may have implications for efficacy of aspirin in this population.
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